866-997-4948(US-Canada Toll Free)

Bladder Cancer - Opportunity Analysis and Forecasts to 2017

Published By :

GlobalData

Published Date : Jan 2016

Category :

Diseases & Conditions

No. of Pages : N/A

The bladder cancer market has remained largely unchanged in the past 10-20 years. However, significant expansion is expected starting in 2016, with the introduction of several new therapies that are projected to fuel market growth. In addition, bladder cancer has a robust early-stage pipeline that will contribute to market growth beyond the forecast period of 2012-2017. Currently, the bladder cancer market is dominated by generic chemotherapy and immunotherapy.

Though initially effective, toxicity and lack of clinical efficacy in improving overall survival have left the door open for more tolerable and effective drugs to be developed. In the past, bladder cancer has not been an area of focus for pharmaceutical companies, but that is rapidly changing as more companies focus on the bladder cancer market, recognizing the high level of unmet need and relatively clear regulatory path. During the forecast period, the market landscape will begin to change dramatically with the introduction of targeted immunotherapies. These drugs will provide much-needed alternatives to bladder cancer patients who have not benefitted from traditional treatments.

Scope

  • Overview of bladder cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized bladder cancer therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for 5 years to 2017.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the bladder cancer therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Table of Contents

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Clinical Staging
3.2 Prognosis
3.3 Quality of Life
3.4 Symptoms
3.5 Diagnosis

4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Co-morbidities
4.2.1 Smoking is the most significant risk factor for bladder cancer
4.2.2 Up to 25% of male bladder cancer cases are due to occupational exposure to aromatic amines
4.3 Global and Historical Trends
4.3.1 Incidence, Mortality, and Five-Year Prevalence
4.3.2 Relative Survival
4.3.3 Disability-Adjusted Life Years and Years of Life Lost
4.4 Forecast methodology
4.4.1 Sources used
4.4.2 Forecast assumptions and methods
4.4.3 Sources not used
4.5 Incident/Prevalent Cases of Bladder Cancer
4.5.1 Incident Cases of Bladder Cancer
4.5.2 Age-Specific Incident Cases of Bladder Cancer
4.5.3 Sex-Specific Incident Cases of Bladder Cancer
4.5.4 Age-Standardized Incidence Rates of Bladder Cancer
4.5.5 Incident Cases of Bladder Cancer by Stage at Diagnosis
4.5.6 Five-Year Prevalent Cases of Bladder Cancer
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis

5 Current Treatment Options
5.1 Overview
5.2 Product Profiles- Major Brands
5.2.1 Intravesical Bacillus Calmette-Guerin
5.2.2 GemCis (Gemcitabine/Cisplatin)
5.2.3 Mitomycin c
5.2.4 Valstar (Valrubicin)
5.2.5 Javlor (Vinfluinine Ditartrate)

6 Unmet Needs Assessment and Opportunity Analysis
6.1 Overview
6.2 Unmet Needs Analysis
6.2.1 Higher Cure Rate for Patients with NMIBC
6.2.2 Therapies that Prevent Disease Progression in Patients with NMIBC
6.2.3 More Efficacious Therapies for Muscle-Invasive and Metastatic Bladder Cancer
6.2.4 Treatment Options for Platinum-Refractory/Intolerant Metastatic Patients
6.2.5 Lack of Predictive Biomarkers
6.2.6 Improved Initial Diagnosis and Resection Success Rates
6.3 Opportunity Analysis
6.3.1 Replacement for BCG Therapy in the NMIBC Setting
6.3.2 Salvage Therapy after BCG Failure in High-Grade Patients
6.3.3 Redefining the Standard of Care for First-Line Muscle-Invasive and Metastatic Patients
6.3.4 Novel Treatments for Platinum-Refractory Patients
6.3.5 Leveraging the Immune System to Fight Bladder Cancer
6.3.6 Identification of Predictive Biomarkers and Targeted Drugs
6.3.7 Neoadjuvant Therapy
6.3.8 Companion Diagnostic Tests

7 R&D Strategies
7.1 Overview
7.1.1 Drug Development by Small Pharmaceutical Companies
7.1.2 Success of BCG Therapy is a Signal for Further Immunotherapy Strategies
7.1.3 Intravesical Approaches for NMIBC May Give Way to Systemic Approaches in the Future
7.2 Clinical trial design
7.2.1 Registrational Studies: Open-Label, Non-Comparative Trial Designs Still Prevalent
7.2.2 A Variety of Trial Endpoints are Used in the NMIBC and Metastatic Settings

8 Pipeline Assessment
8.1 Overview
8.2 Promising drugs in clinical development
8.2.1 MCNA
8.2.2 Apaziquone
8.2.3 Keytruda (Pembrolizumab)
8.2.4 Atezolizumab
8.2.5 Cyramza (Ramucirumab)
8.2.6 Vicinium (Oportuzumab Monatox)
8.2.7 Durvalumab
8.2.8 CG-0070
8.2.9 Apatorsen
8.2.10 Opdivo (Nivolumab)
8.3 Innovative Early-stage Approaches
8.3.1 Immunotherapies
8.3.2 Targeted Therapies

9 Pipeline Valuation Analysis
9.1 Clinical Benchmark of Key Pipeline Drugs
9.2 Commercial Benchmark of Key Pipeline Drugs
9.3 Competitive Assessment
9.4 Top Line Five Year Forecast
9.4.1 US
9.4.2 5EU

10 Appendix
10.1 Bibliography
10.2 Abbreviations
10.3 Methodology
10.4 Forecasting Methodology
10.4.1 Diagnosed Bladder Cancer patients
10.4.2 Percent Drug-treated Patients
10.4.3 Drugs Included in Each Therapeutic Class
10.4.4 Reconciliation of Epidemiological Staging with Clinical Staging
10.4.5 Launch and Patent Expiry Dates
10.4.6 General Pricing Assumptions
10.4.7 Individual Drug Assumptions
10.4.8 Generic Erosion
10.5 Physicians and Specialists Included in this Study
10.6 About the Authors
10.6.1 Author
10.6.2 Therapy Area Director
10.6.3 Epidemiologist
10.6.4 Global Director of Therapy Analysis and Epidemiology
10.6.5 Global Head of Healthcare
10.7 About GlobalData
10.8 Contact Us
10.9 Disclaimer

 

List of Table


Table 1: AJCC TNM Staging System for Bladder Cancer – Definitions of Stages
Table 2: Bladder Cancer Prognosis by Stage
Table 3: Symptoms of Bladder Cancer
Table 4: Bladder Cancer Risk Factors
Table 5: 6MM, GLOBOCAN Incidence, Five-Year Prevalence, and Mortality for Bladder Cancer, Ages =15 Years, Men and Women, 2008
Table 6: 6MM, Relative Survival of Bladder Cancer (%), Men and Women
Table 7: 6MM, GLOBOCAN DALYs and YLLs Due to Bladder Cancer, Men and Women, N, 2008
Table 8: 6MM, Sources of Bladder Cancer Incidence Data
Table 9: 6MM, Incident Cases of Bladder Cancer, Ages =15 Years, Men and Women, N, Selected Years, 2012–2022
Table 10: 6MM, Age-Specific Incident Cases of Bladder Cancer, Ages =15 Years, Men and Women, N (Row %), 2012
Table 11: 6MM, Sex-Specific Incident Cases of Bladder Cancer, Ages =15 Years, Men and Women, N (Row %), 2012
Table 12: 6MM, Incident Cases of Bladder Cancer by Stage at Diagnosis, Ages =15 Years, Men and Women, N (Row %), 2012
Table 13: 6MM, Five-Year Prevalent Cases of Bladder Cancer, Ages =15 Years, Men and Women, N, Selected Years, 2012–2022
Table 14: Leading Treatments for Bladder Cancer
Table 15: Product Profile – TICE-BCG
Table 16: Efficacy of BCG (TheraCys)
Table 17: Safety of BCG
Table 18: BCG SWOT Analysis
Table 19: Product Profile – GemCis
Table 20: Efficacy of GemCis
Table 21: Safety of GemCis
Table 22: GemCis SWOT Analysis
Table 23: Product Profile – Mitomycin C
Table 24: Efficacy of Mitomycin C
Table 25: Safety of Mitomycin C
Table 26: Mitomycin C SWOT Analysis
Table 27: Product Profile – Valstar
Table 28: Efficacy of Valstar
Table 29: Safety of Valstar
Table 30: Valstar SWOT Analysis
Table 31: Product Profile – Javlor
Table 32: Efficacy of Javlor
Table 33: Safety of Javlor
Table 34: Javlor SWOT Analysis
Table 35: Overall Unmet Needs – Current Level of Attainment
Table 36: Clinical Trial Design of Key Pipeline Drugs in the NMIBC Setting
Table 37: Clinical Trial Design of Key Pipeline Drugs in the MIBC and Metastatic Settings
Table 38: Bladder Cancer – Late-Stage Pipeline, 2015
Table 39: Product Profile – MCNA
Table 40: Efficacy of MCNA
Table 41: Safety of MCNA
Table 42: MCNA SWOT Analysis
Table 43: Product Profile – Apaziquone
Table 44: Efficacy of Apaziquone
Table 45: Safety of Apaziquone
Table 46: EOquin SWOT Analysis
Table 47: Product Profile –Keytruda
Table 48: Efficacy of Keytruda
Table 49: Safety of Keytruda
Table 50: Keytruda SWOT Analysis
Table 51: Product Profile – Atezolizumab
Table 52: Efficacy of Atezolizumab in Patients with Locally Advanced or Metastatic Bladder Cancer
Table 53: Efficacy of Atezolizumab in Patients with Locally Advanced or Metastatic Bladder Cancer Previously Treated with Chemotherapy
Table 54: Safety of Atezolizumab in Patients with Locally Advanced or Metastatic Bladder Cancer
Table 55: Safety of Atezolizumab in Patients with Locally Advanced or Metastatic Bladder Cancer Previously Treated with Platinum-Based Chemotherapy
Table 56: Atezolizumab SWOT Analysis
Table 57: Product Profile – Cyramza
Table 58: Efficacy of Cyramza
Table 59: Safety of Cyramza in Combination with Docetaxel
Table 60: Cyramza SWOT Analysis
Table 61: Product Profile –Vicinium
Table 62: Efficacy of Vicinium
Table 63: Safety of Vicinium
Table 64: Vicinium SWOT Analysis
Table 65: Product Profile – Durvalumab
Table 66: Efficacy of Durvalumab
Table 67: Durvalumab SWOT Analysis
Table 68: Product Profile – CG-0070
Table 69: Efficacy of CG-0070
Table 70: Safety of CG-0070
Table 71: CG-0070 SWOT Analysis
Table 72: Product Profile – Apatorsen
Table 73: Efficacy of Apatorsen
Table 74: Safety of Apatorsen
Table 75: Apatorsen SWOT Analysis
Table 76: Product Profile – Opdivo
Table 77: Efficacy of Opdivo
Table 78: Opdivo SWOT Analysis
Table 79: Early-Stage Pipeline Products in Bladder Cancer
Table 80: Clinical Benchmarking of Key Pipeline Drugs – NMIBC setting
Table 81: Clinical Benchmarking of Key Pipeline Drugs – MIBC and Metastatic Settings
Table 82: Commercial Benchmarking of Key Pipeline Drugs – NMIBC setting
Table 83: Commercial Benchmarking of Key Pipeline Drugs – MIBC and Metastatic Settings
Table 84: Top Line Sales Forecasts ($) for Bladder Cancer, 2012-2017
Table 85: Key Events Impacting Sales for Bladder Cancer, 2012–2017
Table 86: Bladder Cancer Market – Drivers and Barriers, US and EU, 2012–2017
Table 87: Key Launch Dates

List of Chart

Figure 1: Competitive Assessment of the Late-Stage Pipeline Agents in Bladder Cancer, 2012–2017
Figure 2: Bladder Cancer Staging Systems
Figure 3: Primary Tumor Development in Bladder Cancer
Figure 4: 6MM, Incidence Rates of Bladder Cancer, Ages =15 Years, Men, Rate per 100,000 Population, 1993–2002
Figure 5: 6MM, Incidence Rates of Bladder Cancer, Ages =15 Years, Women, Rate per 100,000 Population, 1993–2002
Figure 6: 6MM, Incident Cases of Bladder Cancer, Ages =15 Years, Men and Women, N, Selected Years, 2012–2022
Figure 7: 6MM, Age-Specific Incident Cases of Bladder Cancer, Ages =15 Years, Men and Women, N, 2012
Figure 8: 6MM, Sex-Specific Incident Cases of Bladder Cancer, Ages =15 Years, Men and Women, N, 2012
Figure 9: 6MM, Age-Standardized Bladder Cancer Incidence Rate, Ages =15 Years, Men and Women, Cases per 100,000 Population, 2012
Figure 10: 6MM, Incident Cases of Bladder Cancer by Stage at Diagnosis, Ages =15 Years, Men and Women, N, 2012
Figure 11: 6MM, Five-Year Prevalent Cases of Bladder Cancer, Ages =15 Years, Men and Women, N, Selected Years, 2012–2022
Figure 12: Competitive Assessment of Late-Stage Pipeline Agents in Bladder Cancer, 2012–2017
Figure 13: Sales for Bladder Cancer by Region, 2012 and 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Chronic Kidney Disease Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020

    Chronic kidney disease (CKD), which is also known as chronic renal disease, is caused due to progressive loss of proper functioning of the kidneys and associated renal system over a longer period of time either months or years. Chronic kidney diseases often go unnoticed, as the individuals suffering from the disease are seen to be having non-specific symptoms like feeling unwell, or loss of appetite among others. Many a times, patients suffering ...

  • Inflammatory Bowel Disease Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

    Inflammatory bowel disease (IBD) is an immune-mediated disease in which the body’s own immune system attacks the parts of the digestive system of the human body. Such disease involves inflammation of lower gastrointestinal tract and causes irreversible damage to the bowel. Ulcerative colitis and Crohn’s disease are the two major forms of IBD; both having distinct pathologic and clinical characteristics. IBD is a difficult to manage ...

  • Dental Pain Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020

    Dental pain, also referred as toothache is characterized by painful sensation in the teeth or its supporting structures which can be caused by a dental disease or a non-dental disease. Most common causes of toothache are dental cavity (pulpitis), gum disease, a damaged filling, tooth decay, tooth fracture, abscessed tooth, apical periodontitis, and alveolar osteitis. Non-dental causes include muscle pain, maxillary sinusitis, angina pectoris, psy...